Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole effect on regorafenib pharmacokinetics in mCRC or GIST
NL-OMON43377Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of regorafenib and esomeprazole in metastatic colorectal adenocarcinoma (mCRC) and gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Erasmus MC. Primary endpoint: Area under the concentration-time curve of regorafenib. Started May 2016; status: recruiting.
02
Drugs
regorafenibesomeprazole
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON43377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43377.